[Microchip Bio: Clinical trial application for CS231295 tablets accepted] On November 13, Microchip Bio (688321.SH) announced that the company and its wholly-owned subsidiary Shenzhen Microchip Pharmaceuticals recently received the "Acceptance Notice" issued by the Drug Evaluation Center of the State Food and Drug Administration, and the clinical trial application for the independently developed CS231295 tablets for the combination treatment of glioblastoma was accepted. The drug is a new AuroraB highly selective multi-target protein kinase inhibitor with good blood-brain barrier permeability. Phase I data show preliminary anti-tumor activity in patients with recurrent or progressive glioblastoma. This application is a new drug clinical trial application. If no negative or questioning opinions are received within 60 days from the date of acceptance, the company can carry out clinical trials according to the plan, but there is uncertainty about whether it can ultimately be carried out.